Abstract
AMONG the α,ω-substituted sugar-alcohols the dibromo derivatives represent a special group because of their biological properties1. The first dibromo-hexitol introduced into clinical use, the dibromo-mannitol (‘Myelo-bromolR’), has myelotoxic effects2. Its diastereoisomer dibromo-dulcitol (DBD) revealed, in pharmacological experiments, remarkable qualities.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Institóris, L., Horváth, P., and Csányi, E., Proc. Second Intern. Symp. Chemotherapy, Naples 1961 (edit. by Karger, B.), III, 250 (1963).
Eckhardt, S., Sellei, C., Horváth, P., and Institóris, L., Cancer Chemotherapy Reports, 33, 57 (1963).
Sugár, J., Arzneimittel-Forsch. (in the press).
Gáti, E., Arzneimittel-Forsch. (in the press).
Pályi, I., Arzneimittel-Forsch. (in the press).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
KELLNER, B., NÉMETH, L., HORVÁTH, P. et al. 1,6-Dibromo-1,6-dideoxy-dulcitol: a New Antitumoral Agent. Nature 213, 402–403 (1967). https://doi.org/10.1038/213402a0
Issue Date:
DOI: https://doi.org/10.1038/213402a0
This article is cited by
-
New drugs under clinical evaluation in the United States
Cancer Chemotherapy and Pharmacology (1978)
-
Comparative studies on the in vivo distribution pattern of dibromodulcitol and diepoxydulcitol
Zeitschrift f�r Krebsforschung und Klinische Onkologie (1973)
-
Untersuchungen �ber den Zusammenhang von biologischen Wirkungsunterschieden und Verteilungsparametern bei 1,6-Dibromhexiten
Zeitschrift f�r Krebsforschung (1971)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
